Cargando…

Lipoxin A4 as a possible mediator of the beneficial actions of phosphodiesterase-5 enzyme inhibitors

Detalles Bibliográficos
Autor principal:	Das, Undurti N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5206380/ https://www.ncbi.nlm.nih.gov/pubmed/28144281 http://dx.doi.org/10.5114/aoms.2017.64723

Ejemplares similares

Lipoxins as biomarkers of lupus and other inflammatory conditions
por: Das, Undurti N
Publicado: (2011)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
por: Gupta, Nitesh, et al.
Publicado: (2020)

Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal Stem Cells in COVID-19
por: Das, Undurti N
Publicado: (2020)

PUFAs, BDNF and lipoxin A4 inhibit chemical-induced cytotoxicity of RIN5F cells in vitro and streptozotocin-induced type 2 diabetes mellitus in vivo
por: Bathina, Siresha, et al.
Publicado: (2019)

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
por: Ikumi, Kyoko, et al.
Publicado: (2021)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
por: Giorgi, Mauro, et al.
Publicado: (2020)

Lipoxin and Aspirin-Triggered Lipoxins
por: Romano, Mario
Publicado: (2010)

Rolipram: Eotaxin and phosphodiesterase IV inhibitor versus bronchial hyper-reactivity response
por: Khan, Hamza Hassan, et al.
Publicado: (2015)

Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—a possible prevention strategy for COVID-19?
por: Kukreja, Rakesh C., et al.
Publicado: (2022)

Aspirin-triggered 15-epi-lipoxin A(4) signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation
por: Petri, Marcelo H., et al.
Publicado: (2015)

Albumin infusion for the critically ill – is it beneficial and, if so, why and how?
por: Das, Undurti N
Publicado: (2015)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Lipoxin Receptors
por: Romano, Mario, et al.
Publicado: (2007)

Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins
por: Serhan, Charles N., et al.
Publicado: (2002)

Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing
por: Svensson, Camilla I., et al.
Publicado: (2007)

A role for lipoxin A(4) as an anti-inflammatory mediator in the human endometrium
por: Macdonald, Linsay J, et al.
Publicado: (2011)

Arachidonic and eicosapentaenoic acids induce oxidative stress to suppress proliferation of human glioma cells
por: Hari, Anasuya Devi, et al.
Publicado: (2020)

Beneficial Actions of Essential Fatty Acids in Streptozotocin-Induced Type 1 Diabetes Mellitus
por: Shen, Junhui, et al.
Publicado: (2022)

Prevalence of Phosphodiesterase-5 Inhibitor Use in the VHA in 2004 and 2005 Is Twice That of a Commercial Health Plan in 2001
por: French, Dustin D., et al.
Publicado: (2006)

The effect of Lipoxin A(4 )on the interaction between macrophage and osteoblast: possible role in the treatment of aseptic loosening
por: Li, Gang, et al.
Publicado: (2009)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions
por: Kang, Byung Woo, et al.
Publicado: (2022)

Activation of Lipoxin a(4) Receptors by Aspirin-Triggered Lipoxins and Select Peptides Evokes Ligand-Specific Responses in Inflammation
por: Chiang, Nan, et al.
Publicado: (2000)

Evidence of this speculation is needed before the possible beneficial effect of the ketogenic diet can be attributed to the increase in wild‐type mtDNA
por: Finsterer, Josef
Publicado: (2023)

Synthesis of aromatic lactone analogues of Lipoxin A4
por: Ismael, Aya, et al.
Publicado: (2022)

Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
por: Bedi, Pallavi, et al.
Publicado: (2022)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Simvastatin and Benznidazole-Mediated Prevention of Trypanosoma cruzi-Induced Endothelial Activation: Role of 15-epi-lipoxin A4 in the Action of Simvastatin
por: Campos-Estrada, Carolina, et al.
Publicado: (2015)

Lipoxin A(4) and Neutrophil/Lymphocyte Ratio: A Possible Indicator in Achieved Systemic Risk Factors for Periodontitis
por: Doğan, Burak, et al.
Publicado: (2015)

Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: A review
por: Das, Undurti N.
Publicado: (2018)

Modulation of pro-inflammatory and pro-resolution mediators by γ-linolenic acid: an important element in radioprotection against ionizing radiation
por: Poorani, Rangachar, et al.
Publicado: (2020)

Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities
por: Asif, Mohammad
Publicado: (2012)

The 2019 Coronavirus Disease (COVID-19): Possible Psychological Effects and Necessary Actions
por: Goudarzian, Amir Hossein
Publicado: (2021)

Lipoxin A(4) and 15-Epi-Lipoxin A(4) Protect against Experimental Cerebral Malaria by Inhibiting IL-12/IFN-γ in the Brain
por: Shryock, Nathaniel, et al.
Publicado: (2013)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
por: Dhawan, Manish, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aj6jdufcjgt42qcds20l9bsnv5